RCS - OptiBiotix Health - Investor presentation <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

20/01/2016 07:10

RNS Number : 3688M
OptiBiotix Health PLC
20 January 2016
OptiBiotix Health Plc
(the "Company" or the "Group")
Investor Presentation 
OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it will be holding a presentation for investors on Tuesday, 16th February 2016. 
The event will be held in the Black Bar, upstairs at Rocket Bar, 6 Adams Court, Old Broad Street, London EC2N 1DX from 4.30pm for a 4.45pm start.
A presentation will be given by founder & CEO of OptiBiotix, Stephen O'Hara, for approximately one hour. The presentation will include an overview of the Company, where they are currently positioned and their plans for the future. This will be followed by light refreshments and an opportunity to network. 
To register for the event, please email optibiotix@walbrookpr.com or call the Walbrook PR team below. 
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below


Cairn Financial Advisers LLP
Tel: 020 7148 7900
Liam Murray / Avi Robinson



Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3764 2341
Peterhouse Corporate Finance Ltd (Joint Broker)
Tel: 020 7469 0936
Lucy Williams / Duncan Vasey



Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
Mike Wort
Mob: 07900 608 002
About OptiBiotix Health PLC - www.optibiotix.com 
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRAGGUPPGUPQGMB